Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Depreciation & Amortization (CF) (2016 - 2025)

vTv Therapeutics (VTVT) has disclosed Depreciation & Amortization (CF) for 12 consecutive years, with $2000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 90.91% to $2000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16000.0 through Dec 2025, down 82.02% year-over-year, with the annual reading at $16000.0 for FY2025, 82.02% down from the prior year.
  • Depreciation & Amortization (CF) hit $2000.0 in Q4 2025 for vTv Therapeutics, roughly flat from $2000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $31000.0 in Q4 2022 to a low of $2000.0 in Q3 2025.
  • Historically, Depreciation & Amortization (CF) has averaged $19200.0 across 5 years, with a median of $22000.0 in 2021.
  • Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 40.91% in 2022 and later tumbled 90.91% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $22000.0 in 2021, then soared by 40.91% to $31000.0 in 2022, then dropped by 25.81% to $23000.0 in 2023, then fell by 4.35% to $22000.0 in 2024, then crashed by 90.91% to $2000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for VTVT at $2000.0 in Q4 2025, $2000.0 in Q3 2025, and $3000.0 in Q2 2025.